Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, Applied Biosystems

Qiagen this week released three new RNAi related products.
The first is the FlexiPlate siRNA, a line of 96-well plates in 0.1 nmol, 0.25 nmol, and 1 nmol scales for use with human or mouse target genes.
SiRNAs and controls, Qiagen said, can be selected and arranged on the plates using a Web-based interface.
The company has also released the HP OnGuard siRNA design algorithm.
The algorithm incorporates a neural-network algorithm and proprietary homology analysis, in addition to other new features including 3' UTR/seed region analysis, SNP avoidance, and interferon motif avoidance, Qiagen said.
Lastly, Qiagen introduced the Human Druggable Genome siRNA set 3.0, which targets more than 7,000 genes of therapeutic value. SiRNAs are available through the set either individually or in pools.

Applied Biosystems has introduced new TaqMan microRNA assays, including assays for human, mouse, Drosophila, and C. elegans genes.
The new assays are in addition to the company’s existing assays for rat and Arabidopsis genes and increase the complete TaqMan miRNA assay collection to 571.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.